Chicago Atlantic BDC has moved within a fairly tight range lately, sitting close to the $9.00 mark. The most recent close at $8.99 follows a level around $9.14 from about 30 days prior, which works out to a modest drop of roughly 1.6% over that period. Daily and intraday swings have stayed contained, which fits the profile of a BDC where value tends to track net asset value, dividend payouts, and credit performance more than sharp earnings momentum.
Market sentiment around the name has been influenced by broader specialty finance trends tied to interest rates and credit conditions, along with the specific news around the proposed combination with Chicago Atlantic Real Estate Finance. The relative stability aligns with the typical investor base for these vehicles, which often prioritizes yield and book value stability over price momentum.
Chicago Atlantic BDC, Inc. operates as a specialty finance firm that has elected BDC status under the Investment Company Act of 1940 and RIC treatment for tax purposes. Its goal centers on delivering attractive risk-adjusted equity returns through direct loans to privately held middle-market businesses, with a core emphasis on cannabis operators.
The firm is advised by Chicago Atlantic BDC Advisers, LLC, drawing on a platform with deep experience in cannabis and other less-covered lending areas. Its edge comes from this focused niche: as one of the few public BDCs centered on cannabis lending, it can source senior secured loans at solid yields in a space where many traditional lenders face federal hurdles. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The standout item remains the planned merger with Chicago Atlantic Real Estate Finance (REFI). Both boards approved the deal, which aims to merge complementary portfolios, grow the overall platform, and expand origination capacity. Completion is targeted for the fourth quarter of 2026, after which a $25 million share repurchase program is slated to begin, subject to conditions and approval.
Earnings updates continue as well, with third-quarter 2026 results released on November 12, 2026. Management has highlighted a book heavy on senior secured positions and a double-digit trailing gross effective yield. There is also an ongoing push to broaden exposure beyond cannabis into lower-middle-market lending, an effort the merger is expected to support.
Going forward, the main near-term focus will be on closing and integrating the REFI transaction. Attention will turn to whether the combined entity delivers the scale and diversification outlined by management, along with execution on the planned buyback. Dividend sustainability and net asset value trends should stay front and center for income-focused holders.
Portfolio credit quality in the cannabis segment, interest rate moves, and any regulatory shifts affecting cannabis lending will also matter. Because earnings come primarily from loan interest, borrower performance and credit spread changes can affect both distributions and book value. Competitive dynamics in specialty finance and the pace of new originations complete the list of items worth tracking through the rest of 2026.
From what I see, tools that surface algorithmic strategies can add a useful layer when evaluating names like this. Tickeron’s AI Trading Bots platform offers a range of automated approaches that monitor thousands of tickers across different timeframes and risk profiles. I find it helpful to review top-performing bots on their Trending AI Robots page for additional context on how systematic signals are behaving around a given holding.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
LIEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 49 cases where LIEN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for LIEN just turned positive on October 27, 2026. Looking at past instances where LIEN's MACD turned positive, the stock continued to rise in 27 of 51 cases over the following month. The odds of a continued upward trend are 53%.
Following a +1.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIEN advanced for three days, in 111 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIEN as a result. In 79 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The Aroon Indicator for LIEN entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. LIEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.684) is normal, around the industry mean (2.423). P/E Ratio (6.525) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.318). Dividend Yield (0.150) settles around the average of (0.274) among similar stocks. P/S Ratio (5.811) is also within normal values, averaging (15.906).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InvestmentManagers